Infliximab and Adalimumab Use During Breastfeeding

Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation

“…None of the infants in the available studies exhibited signs of adverse reactions to the maternal medication. 110,175,176 Similar findings were made when examining serum and breast milk levels in patients treated with CZP and their neonates. 177 Small amounts of Infliximab, ADA and CZP as well as golimumab might be transferred to the infant via breast milk.…”

“…One case report could not find ADA in the serum of the infant while the mother received scheduled therapy. None of the infants in the available studies exhibited signs of adverse reactions to the maternal medication . Similar findings were made when examining serum and breast milk levels in patients treated with CZP and their neonates .…”

Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy

“…A case report by Ben-Horin et al [78] and two cases followed by Fritzsche et al [75] for 14.5 and 15 months, respectively, did not show any significant adverse effects in the infants. As a consequence of this data, this drug has been deemed compatible for use in pregnancy and breastfeeding [76].…”

“…Several studies have negated the presence of IFX in breast milk and shown compatibility with breastfeeding [50,51,70,[72][73][74][75][76][77]. However, reports from Ben-Horin et al found very low concentrations of IFX and ADA in breast milk of exposed women [75,78,79]. The fact that all large molecules are broken down by enzymes in the gut before being absorbed means most of the drug in the breast milk will also be enzymatically broken down into smaller molecules.…”

Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy

“…Several studies have negated the presence of IFX in breast milk and shown compatibility with breastfeeding [50,51,70,[72][73][74][75][76][77]. However, reports from Ben-Horin et al found very low concentrations of IFX and ADA in breast milk of exposed women [75,78,79].…”